Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine. The study aims to assess the efficacy, safety, and tolerability of Atogepant, an investigational drug, for preventing menstrual migraines in adult women.
The intervention being tested is Atogepant, an oral tablet designed to prevent menstrual migraines. Participants are randomly assigned to receive either Atogepant or a placebo during the double-blind period, followed by Atogepant in the open-label period.
This interventional study uses a randomized, parallel assignment model with triple masking (participant, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused.
The study began on February 10, 2025, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 25, 2025.
The study’s progress could influence AbbVie’s stock performance and investor sentiment, especially as the company seeks to expand its migraine treatment portfolio. Competitors in the migraine treatment market will be closely watching these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.